Stockwinners Market Radar for December 13, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST Surrozen Inc trading halted, news pending

19:50 EST Genetic Technologies trading halted, news pending

18:37 EST Robinhood CEO Tenev sells 250,000 class A shares - In a regulatory filing, Robinhood Markets CEO Vladimir Tenev disclosed the sale of 250,000 class A common shares of the company on December 11 at a price of $11.6018 per share.

18:25 EST Chanson International announces plan to grow new coffee brand in China - Chanson International Holding announced that the Company had reached a significant milestone in the Chinese market by having operated seven new cafes under the Company's new coffee brand, SoulSong, in China. SoulSong adopts the "blend bean concept," which emphasizes not only the selection of high-quality coffee beans but also the art of blending different coffee beans. This method allows for the fusion of multiple flavors, the creation of varied and complex flavors, and the provision of a wider range of choices to the customers. Gang Li, Chairman of the Board of Directors and Chief Executive Officer of the Company, commented, "China's consumer market is showing signs of recovery from the COVID-19 pandemic, with consumer preferences becoming increasingly diverse and evolving. We have tailored our new SoulSong brand to meet these changing tastes. With the successful opening of seven new cafes under the brand, we are poised to continuously expand our footprint in 2024, embarking on a franchise or direct operation model to accelerate the growth of our number of cafes. We believe that SoulSong is a testament to our capability to align with and appeal to the evolving trend of the customers, helping create long-term value for our shareholders."

18:09 EST Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share - Rain Oncology has entered into a definitive merger agreement whereby Pathos AI will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately 17c per share. The Rain Board of Directors voted unanimously to approve the proposed transaction. The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13. A subsidiary of Pathos will commence a tender offer to acquire all outstanding shares of Rain for $1.16 in cash per share plus a CVR representing a contractual right to receive two potential contingent aggregate cash payments as follows: an aggregate amount equal to $5.0M - up to approximately 14c per share -, minus certain expenses incurred related to pending or future litigation involving Rain and its directors or officers, minus any shortfall in a target level of net cash, plus (C) any cash at closing in excess of the target net cash; a development CVR Payment of either $1.0M or approximately 3c per share, upon the first patient dosed in a clinical stage study conducted by Pathos using milademetan within five years of the closing of the merger; or 80% of the net proceeds from any license or disposition of milademetan effected within two years of the closing of the merger. The closing of the tender offer is subject to certain conditions, including the tender of Rain shares representing at least one share more than 50% of the total number of outstanding shares of common stock as of immediately prior to consummation of the tender offer; the availability of at least $49.6M of cash and cash equivalents, net certain liabilities at closing; and other customary conditions. Following the tender offer closing, this subsidiary will be merged into Rain with Rain as the surviving entity of the merger, which will then operate as a separate, wholly-owned subsidiary of Pathos. If the tender offer is successful, the Transaction is expected to close in January 2024.

18:00 EST Rain Therapeutics trading halted, news pending

17:55 EST AppLovin officer Valenzuela sells $965K in company shares - Officer of Applovin Victoria Valenzuela disclosed the sale of 26,097 shares of company stock on November 23 at $36.98 per share, for a total transaction amount of $965,091.

17:48 EST Carrier Global sells Commercial Refrigeration business for $640M - Carrier Global entered into a stock purchase agreement with Haier Smart Home whereby Haier will acquire Carrier's Commercial Refrigeration Business through acquiring 100% of the equity interest in Carolin Holdings B.V. Carrier, for total consideration of approximately $640M, which represents 11x 2022A P/E. The transaction is expected to close in the second half of 2024, and is subject to regulatory approvals and customary closing conditions, and works council consultation processes.

17:39 EST JPE reports 38.2% stake in SilverSun Technologies in 13d - As a result of the Voting and Support Agreement, JPE may be deemed for the purposes of Rule 13d-3 promulgated under the Exchange Act to beneficially own 2,006,534 Shares and Mr. Jacobs may be deemed for the purposes of Rule 13d-3 promulgated under the Exchange Act to indirectly beneficially own 2,006,534 Shares. This number of Shares represents, for the purposes of Rule 13d-3, approximately 38.2% of the outstanding shares of voting stock of the Company based on the Company's representations in the Investment Agreement that there were 5,266,177 Shares issued and outstanding at the close of business on December 3. The Reporting Parties disclaim any beneficial ownership of such Shares, and nothing herein shall be deemed to be an admission by the Reporting Parties as to the beneficial ownership of such Shares.

16:58 EST Adobe falls 6% to $584.38 after Q1, FY24 revenue guidance misses estimates

16:47 EST Osisko Gold sells common shares of Osisko Mining for proceeds of C$132M - Osisko Gold has sold 50,023,569 common shares of Osisko Mining pursuant to a bought block trade with National Bank Financial and BMO Capital Markets for aggregate gross proceeds of approximately C$132M. Following the transaction, the corporation no longer holds any common shares of Osisko Mining. The corporation continues to hold its 2.0 to 3.0% NSR royalty on the Windfall Gold Project and the surrounding property, held by a 50/50 joint-venture partnership between Osisko Mining and Gold Fields.

16:41 EST Streamline Health signs new contract RevID with a 2,300-bed health system - The Company also announced that it has signed a new contract for the use of RevID with a 2,300-bed health system based in Maryland. Streamline is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID's automated charge reconciliation ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide.

16:35 EST EOG Resources promotes Jeffrey Leitzell to COO, Ann Janssen to CFO - EOG Resource announced that Jeffrey Leitzell has been promoted to executive VP and COO effective December 18. Lloyd Helms, Jr., currently president and COO, will continue serving as president. EOG also announced that Ann Janssen will be promoted to executive VP and CFO, effective January 1, 2024, and that Laura Distefano, VP, accounting, will succeed Ann as VP and chief accounting officer. Timothy Driggers, EOG's executive VP and CFO, will continue serving as an advisor to allow for the transition of his responsibilities prior to retirement in 2024. Tim Driggers has been an EOG employee for 28 years, having joined a predecessor company in 1995. Tim has served as EOG's principal financial officer since 2007 following a successful career leading the finance, accounting, and land administration functions at EOG.

16:34 EST Pembina to acquire Enbridge interests in JVs for aggregate price of about $3.1B - Pembina Pipeline Corporation (PBA) announced that it has entered into an agreement with Enbridge Inc. (ENB) to acquire all of Enbridge's interests in the Alliance, Aux Sable and NRGreen joint ventures. Pembina has entered into an agreement to acquire Enbridge's interests in Alliance, Aux Sable and NRGreen for an aggregate purchase price of approximately $3.1 billion (subject to certain adjustments), including approximately $327 million of assumed debt, representing Enbridge's proportionate share of the indebtedness of Alliance (the "Acquisition"). The cash portion of the Acquisition will be funded through a combination of: (i) the net proceeds of a $1.1 billion bought deal offering of subscription receipts; and (ii) amounts drawn under Pembina's existing credit facilities and cash on hand. Complements Pembina's strategy of providing access for world-class, long-life resources from the Western Canadian Sedimentary Basin ("WCSB") to premium end markets and increases exposure to lighter hydrocarbons, including natural gas and NGL. Immediately accretive to adjusted cash flow per share, with mid-single digit accretion expected to be achieved in the first full year of ownership, inclusive of synergies. Additional long-term synergy opportunities have been identified that are expected to drive incremental accretion. The Acquisition is expected to be leverage neutral, ensuring Pembina's continued financial flexibility to fund future projects, and enhances its free cash flow position. Aligned within Pembina's financial guardrails, consistent with a strong BBB credit rating, and an unchanged business profile with 85% to 90% fee-based contribution to adjusted EBITDA with a high-degree of take-or-pay commitments. The Acquired Business (defined below) is estimated to be 80% to 90% fee-based. Attractive acquisition multiple of approximately 9x 2023 and 2024 forecasted adjusted EBITDA, or approximately 8x 2023 and 2024 forecasted adjusted EBITDA, inclusive of $40 million to $65 million of annual synergies expected to be realized by 2025. Additional long-term synergy opportunities have been identified that would further reduce the transaction multiple. The Acquisition is expected to close in the first half of 2024, subject to the satisfaction or waiver of customary closing conditions, including the receipt of required regulatory approvals.

16:32 EST Certara acquires Applied BioMath - Certara has acquired Applied BioMath, a provider of model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development. Certara and Applied BioMath are the life sciences industry's largest team of experts in quantitative systems pharmacology - QSP -, a method of biosimulation used across the development lifecycle to predict endpoints, biomarkers and the most effective dosing regimen. QSP combines computational modeling and experimental data to examine the relationships between a drug, the biological system, and the disease process. The resulting insights help scientists answer critical questions about novel therapies required for development progression including which patient populations are most likely to respond.

16:31 EST Brinker CFO Taylor sells almost $660K in company shares - The CFO of Brinker International JosephTaylor disclosed the sale of 16,000 shares of company stock at $41.14 per share between December 11 and December 12, for a total transaction amount of $658,259.

16:26 EST NYSE to commence delisting proceedings against Regis - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Regis Corporation - ticker symbol RGS - from the NYSE. "NYSE Regulation has determined that the company is no longer suitable for listing pursuant to Section 802.02 of the Listed Company Manual as the company was unable to demonstrate that it had regained compliance with the applicable listing standard by the expiration of the maximum plan period... The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange," the NYSE stated.

16:20 EST Mueller Water sees FY24 capital expenditures $45M-$50M - Sees FY24 effective tax rate 23%-25%. The company said, "The Company anticipates that channel and customer inventory levels will be substantially normalized by the end of the first quarter of fiscal 2024. At the end of fiscal 2023, iron gate valve and hydrant backlogs were normalized, while the backlog for service brass products remained elevated. Due to these factors, the Company expects to face volume headwinds in fiscal 2024 relative to the prior year and anticipates that consolidated net sales will decrease between 3 and 8 percent as compared with fiscal 2023. For fiscal 2024, consolidated net sales seasonality is expected to be closer to pre-pandemic patterns. For example, net sales for the first half of the fiscal year averaged approximately 45 percent of consolidated net sales for the 5-year period from 2015 to 2019. For the first quarter of fiscal 2024, the Company anticipates its consolidated net sales to range between $245 million and $255 million. The Company continues to evaluate the business, financial and related impacts of the cybersecurity incident announced on October 28, 2023, so the full costs of the incident have not yet been determined. However, the Company anticipates the incident will negatively impact the Company's results. Due to the need for further evaluation of the impacts of the incident, the Company will not provide profitability and margin guidance for the fiscal year at this time. However, the Company currently expects margins to improve in the second half of the year primarily due to its focus on operational and supply chain productivity improvements."

16:17 EST MAA appoints Brad Hill President and Chief Investment Officer - MAA has promoted Bradley Hill to the role of President and Chief Investment Officer. Hill joined MAA in 2010 and has over 20 years of real estate experience in the areas of transactions, development, and operations. Hill has most recently served as Executive Vice President and Chief Investment Officer with oversight of the company's transactions and development operations.

16:16 EST Cargo Therapeutics gives update, begins Phase 2 clinical trial of of CRG-022 - Cargo Therapeutics gives update, beginsPhase 2 clinical trial of of CRG-022 CARGO announced that it has dosed the first seven patients in its potentially pivotal Phase 2 multicenter clinical trial after successfully manufacturing CRG-022, the Company's autologous CD22 chimeric antigen recepto CAR T-cell product candidate. CD22 is a common B-cell antigen widely expressed in the vast majority of B-cell malignancies, including LBCL. The clinical trial is an open-label, multicenter Phase 2 clinical trial evaluating the efficacy and safety of CRG-022 in patients with R/R LBCL whose disease has progressed after CD19-directed CAR T-cell therapy, an area of high unmet need."This year has been transformational for our company. We experienced growth across our business, including expanding our leadership team, commencing a Phase 2 clinical trial of CRG-022, and becoming a publicly traded company," said Gina Chapman, President and Chief Executive Officer of CARGO. "While CAR T-cell therapies have changed the treatment landscape for patients with LBCL, patients whose disease relapses or is refractory to CD19 CAR T-cell therapy face a median survival of less than 6 months. We continue to believe that CRG-022 has the potential to alter the treatment paradigm for patients whose disease has relapsed or is refractory to CD19 CAR T. We are very pleased to have started our Phase 2 clinical trial which represents a key milestone as we work toward our goal of developing and delivering potentially curative therapies to more patients."

16:13 EST Nxu Inc. signs LOI for investment in Lynx Motors - Nxu, Inc. has signed a letter of intent, or LOI, outlining a strategic investment in Lynx Motors. As a strategic partner, Nxu intends to assist Lynx in leveraging Nxu's vehicle and charging technology to more quickly scale its development of electrified products. Lynx is reimagining classic vehicles with a vision toward modernization and electrification, allowing owners to enjoy the original character and design of a classic car with modern amenities and powertrains. In addition to the strategic value, this transaction is a step toward the execution of Nxu's Nasdaq compliance plan, which will increase Nxu's shareholder equity and help to ensure that Nxu achieves and maintains Nasdaq's listing standards. Additionally, Lynx Motors is working to electrify some of the most popular cars of all time and boasts a robust reservation list and projects to rapidly scale to gain significant revenue and prompt profitability. Lynx has already been successful converting premium-branded SUVs into vehicles with today's conveniences and high-powered engine performance and is now turning this success to electrification.

16:12 EST Veradigm says Nasdaq panel grants continued listing - Veradigm announced that it received a decision from the Nasdaq Hearings Panel granting its request for continued listing on the Nasdaq Capital Market, subject to the company demonstrating compliance with Nasdaq Listing Rule 5250(c)(1) on or before February 27, 2024, and certain other conditions, including the achievement of various interim milestones.

16:11 EST Robinhood reports November operating data - Robinhood reported selected monthly operating data for November. Net cumulative funded accounts, or NCFA, at the end of November were 23.3M, up approximately 20,000 from October. Assets under custody, or AUC, at the end of November were $94.4B, up 12% from October. Net deposits were $1.4B in November, translating to a 20% annualized growth rate relative to October AUC. Over the last twelve months, net deposits were $16.4B, translating to an annual growth rate of 23% relative to November 2022 AUC. Trading volumes in November were roughly in line with October for equities and options, and were higher for crypto. Equity notional trading volumes were $52.9B. Options contracts traded were 95.3M. Crypto notional trading volumes were $4B. Margin balances at the end of November were $3.4B, down 3% from October. Total cash sweep balances at the end of November were $15.2B, up $1.3B from the end of October.

16:08 EST Light & Wonder names Oliver Chow CFO - Light & Wonder announced that Oliver Chow has been appointed as the Company's Executive Vice President, Chief Financial Officer, and Treasurer. He has served as Interim CFO since August 2023 and previously served as the Company's Senior Vice President of Corporate Finance. Matt Wilson, Chief Executive Officer of Light & Wonder, said, "After a thorough search by the Board and the leadership team, I'm pleased to appoint Oliver as our CFO. Over the last four months, we've all been impressed with Oliver's ability to seamlessly step into the role of Chief Financial Officer. With more than 15 years of entertainment and gaming leadership experience and deep financial expertise, Oliver was the candidate best positioned to lead us forward. His attention to detail, combined with his willingness to take on a wider variety of challenges within the organization with ease, has made us resolute in our decision."

16:03 EST Preferred Bank increases quarterly dividend 27.3% to 70c per share - Preferred Bank reported that the board of directors has increased the quarterly cash dividend to 70c per share from the previous level of 55c per share, an increase of 27.3%. The dividend is payable on January 22 to holders of record on January 8.

16:01 EST Amgen granted Priority Review by FDA for BLA for tarlatamab - Amgen announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the company's Biologics License Application for tarlatamab. Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 targeting Bispecific T-cell Engager therapy for the treatment of adult patients with advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy. Based on the Priority Review designation, the Prescription Drug User Fee Action date for tarlatamab is June 12, 2024.

15:19 EST Microsoft Xbox cloud gaming now viable on Meta's Quest VR headsets - Joe Skrebels, Xbox Wire Editor-in-Chief, blogged in part earlier: "At Xbox (MSFT), we're always looking to make gaming available to more people on more devices. Starting today Xbox Cloud Gaming (Beta) is now available on Meta (META) Quest 3. You can play hundreds of games with a Meta Quest 2, 3, or Pro headset, the latest Quest software update, an Xbox Game Pass Ultimate membership, a supported controller, and a high-speed internet connection.Experience your favorite games like Starfield and Forza Motorsport on a huge virtual screen, or discover ID@Xbox gems like Unpacking playable on the go. You can also enjoy classics like Fallout 4 and Star Wars Jedi: Fallen Order or have some fun with Goat Simulator and LEGO Star Wars that are currently available to play with your Game Pass membership. And the best part is, you can play them anywhere, anytime, and however you want to play." Reference Link

14:34 EST Vivendi exploring split of company into several entities - Vivendi said that since the distribution and listing of Universal Music Group in 2021, it "has endured a significantly high conglomerate discount, substantially reducing its valuation and thereby limiting its ability to carry out external growth transactions for its subsidiaries. Canal+, Havas and Lagardere are currently experiencing strong growth in an international context marked by numerous investment opportunities. In order to fully unleash the development potential of all its activities, the Management Board of Vivendi proposed to the Supervisory Board - which gave its approval on the matter today - to explore the feasibility of a project to split the company into several entities, each of which would be listed on the stock market and structured around" Canal+, Havas and an investment company with listed and unlisted financial stakes in the cultural, media and entertainment sectors, which would include the majority stake in the Lagardere group. Vivendi added, "This split project would provide all the entities with the human resources and the financial agility necessary for their development. This project will have to prove its added value for all stakeholders and include an analysis of the tax consequences of the various contemplated operations. To conduct this study, Vivendi will be assisted by its usual banks and advisors."

14:13 EST ADiTx Therapeutics trading resumes

13:54 EST Netflix reveals 2024 mobile games, 'Squid Game' and 'Rebel Moon' games coming - Earlier on wednesday the streamer announced, in part..."with a more robust games catalog, we're now curating the mobile games row so it's most relevant for each member. As we grow our games selection and more members play our games, these recommendations will evolve and improve over time. By year's end, we'll have 86 games available -all included with every Netflix membership without ads, in-app purchases or extra fees.... Find more information on our upcoming game releases: Cozy Grove: Camp Spirit - Coming 2024...Embark on a heartwarming adventure in Cozy Grove: Camp Spirit, the sequel to Spry Fox's beloved life-sim game Cozy Grove...FashionVerse - Coming 2024...Your game, your style. Design your own fashion, become a trendsetter... Show off your creativity, earn rewards, and make your mark...Game Dev Tycoon - Coming 2024...Replay the history of the gaming industry by starting your own video game development company in the '80s. Research new technologies and run your business...Sonic Mania Plus - Coming 2024...Exclusive to Netflix Games and on mobile for the first time, experience the ultimate celebration of past and future in Sonic Mania Plus...More games coming soon include: Braid, Anniversary Edition,Chicken Run: Eggstraction, The Dragon Prince: Xadia, Dumb Ways to Survive, Hades,Harmonium, etc: The Musical and The Rise Of The Golden Idol ,A Rebel Moon game developed by Super Evil Megacorp. The game will take place following the events of Rebel Moon - Part One: A Child of Fire and Rebel Moon - Part Two: The Scargiver. Choose your rebel and join the fight in this four-player co-op action game. A game set in the universe of Squid Game, in which you can compete with other players in games from the hit series." Reference Link

13:13 EST B. Riley discloses over $200M loan to Brian Kahn, The Friendly Bear says - The Friendly Bear said on X, formerly known as Twitter, that, "BREAKING NEWS: [B. Riley Financial] $RILY for the first time discloses that they have over a $200MM loan to Brian Kahn on top of $280MM in FRG. This was highly material and undisclosed. It's supposedly secured by $FRG as our research confirmed. Why was this never disclosed?" The tweet included a photo with the disclosure made during the company's Investor Day. Reference Link

12:17 EST Microsoft's Bethesda says 'Fallout 4' next-gen update coming in 2024 - Microsoft's Bethesda said that it needs "a bit more time" to complete its current generation, meaning native Xbox Series X/S, update for 2015 title "Fallout 4." "Thank you for your patience with us as we work on the Fallout 4 next-gen update," the company said. "We know you're excited, and so are we! But we need a bit more time and look forward to an exciting return to the Commonwealth in 2024." Reference Link

12:11 EST 'Call of Duty: MW III' top-selling game in U.S. in November, says Circana - Circana analyst Mat Piscatella said that U.S. November video game content spending dropped 3% when compared to a year ago, to $4.6B. An 11% decline in Console & Portable Content spending was partially offset by 3% growth across each of the Mobile, Subscription, and 'PC, Cloud & Non-Console VR' Content segments. November 2022 featured the launches of both Sony's (SONY) "God of War: Ragnarok" and Nintendo's (NTDOY) "Pokemon: Scarlet/Violet." Activision's (MSFT) "Call of Duty: Modern Warfare III" was the best-selling game of November, instantly becoming the 2nd best-selling game of 2023 year-to-date. It is the 5th consecutive year that a "Call of Duty" title was November's best-seller. Other top sellers for the month of November include "Marvel's Spider-Man 2," Warner Bros. Discovery's (WBD) "Hogwarts Legacy" and "Mortal Kombat 1," Electronic Arts' (EA) "Madden NFL 24" and "EA Sports FC 24," Nintendo's "Super Mario Bros. Wonder" and "Super Mario RPG," and Take-Two's (TTWO) "NBA 2K24."

12:00 EST ProShares UltraShort Bloomberg Natural Gas falls -8.2% - ProShares UltraShort Bloomberg Natural Gas is down -8.2%, or -$9.56 to $107.03.

12:00 EST Medifast falls -13.8% - Medifast is down -13.8%, or -$10.43 to $64.98.

12:00 EST Despegar.com rises 13.9% - Despegar.com is up 13.9%, or $1.18 to $9.68.

11:47 EST Couchbase sees 20%+ growth, positive FCF in FY26 - Couchbase, at its Financial Analyst Day, provided guidance for FY24 and the medium-term. The company sees 14% revenue growth in FY24 and 22% ARR, with medium-term revenue and ARR up 20%+ and medium-term gross margin about 80%. The company expects to deliver 20%+ growth, positive free cash flow in FY26, and non-GAAP operating income in FY27.

11:37 EST BP says former CEO Looney to receive no further salary, announces clawback - Following the September 12 announcement of the resignation of former chief executive officer Bernard Looney, BP p.l.c. announces the decisions that have been taken in relation to his remuneration. "Following careful consideration, the board* has concluded that, in providing inaccurate and incomplete assurances in July 2022, Mr Looney knowingly misled the board. The board has determined that this amounts to serious misconduct, and as such Mr Looney has been dismissed without notice effective on 13 December 2023. This decision had the effect of bringing Mr Looney's 12 month notice period to an immediate end... Mr Looney will be required to repay 50% of the cash portion of the annual bonus paid to him in respect of the financial year 2022 and he will forfeit 6/36ths of his award of shares that vested in August 2023 from the three-year 2020-2022 performance share plan under the EDIP... The total maximum value of the potential remuneration that has been forfeited or clawed back is GBP 32,426,000 based on the assumptions described below. 87% of this value is automatically forfeited as a result of Mr Looney's resignation with immediate effect on 12 September 2023. 10% results from the board's decision that he should be dismissed following serious misconduct and the further 3% has been clawed back at the discretion of the board," BP stated in a notice to the London Stock Exchange.

11:30 EST Chanson International Holding trading halted, volatility trading pause

11:21 EST Etsy announces 11% reduction of Etsy marketplace workforce, or 225 employees - In a regulatory filing, Etsy said that on December 12, the board of directors approved a restructuring plan designed to increase Etsy's operational efficiencies, reduce operating costs, and better align Etsy's workforce and cost structure with current business needs, top strategic priorities and key growth opportunities. The Restructuring Plan includes an approximately 11% reduction of the Etsy marketplace workforce, which is approximately 225 employees, inclusive of management changes Following the Restructuring Plan, headcount for the core Etsy marketplace team is estimated to be approximately 1,770 people, similar to the headcount level early in 2022. The Restructuring Plan is expected to deliver meaningful operational efficiencies and cost savings and/or cost avoidance, particularly related to compensation and benefits. In connection with the Restructuring Plan, Etsy estimates that it will incur approximately $25M-$30M in charges, largely made up of cash expenditures, consisting of severance payments, employee benefits, and related costs. Etsy expects that the charges will be incurred primarily in the fourth quarter of 2023 and that the execution of the Restructuring Plan will be substantially complete by the end of the first quarter of 2024.

11:19 EST Beyond's SG&A must come down 'at least' 30%, says Lemonis - At a fireside chat hosted by Needham, Beyond Chairman Marcus Lemonis said the company must dramatically reduce the fixed expenses and plans to cut SG&A by at least 30%. Lemonis said Beyond must divest or eliminate all non-performing assets "that aren't either growing revenue generating cash or materially improving our share price."

11:04 EST Ambetter of Illinois partners with RUSH University System for Health - Ambetter of Illinois announced a partnership with RUSH University System for Health to increase access to quality healthcare. Ambetter of Illinois members in the Chicagoland area can now receive care at any of the 140 RUSH locations in the region.

10:29 EST Google Cloud and HashiCorp announce expansion of partnership - Google Cloud (GOOGL) and HashiCorp (HCP) announced an expansion of their partnership to build and deliver functional generative AI to enhance automation and accelerate the cloud transformation efforts of their mutual customers. "The two companies will work together to launch new AI-powered features across HashiCorp's product suite, built using Vertex AI. Google Cloud's Vertex AI platform helps customers discover, customize, augment, deploy, and manage their AI projects. Through the partnership, Google Cloud will become a preferred AI provider for HashiCorp. HashiCorp intends to use Vertex AI to develop new interfaces for joint customers to help them use natural language commands and automate common tasks, including dashboard and insight development. In addition, the two companies plan to train new AI models tuned specifically for HashiCorp customers' common use cases. Also today, the companies announced that HashiCorp will add support for Google Cloud's Duet AI for Developers, helping to train Duet AI with product information on Terraform to provide assistance writing configurations and automating infrastructure," the companies stated.

10:24 EST Brilliant Acquisition Corp trading halted, volatility trading pause

10:00 EST Medifast falls -9.5% - Medifast is down -9.5%, or -$7.16 to $68.25.

10:00 EST Gaotu Techedu rises 10.8% - Gaotu Techedu is up 10.8%, or 37c to $3.81.

10:00 EST ABM rises 14.7% - ABM is up 14.7%, or $6.53 to $50.89.

09:48 EST Altamira Therapeutics trading resumes

09:47 EST Community Bancshares falls -5.9% - Community Bancshares is down -5.9%, or -$1.19 to $18.91.

09:47 EST Despegar.com rises 9.1% - Despegar.com is up 9.1%, or 77c to $9.27.

09:47 EST ABM rises 11.5% - ABM is up 11.5%, or $5.09 to $49.45.

09:36 EST Knightscope begins shipping 5th generation K5 ASR - Knightscope announces the release of the 5th Generation K5 Autonomous Security Robot. K5v5 production has commenced in Silicon Valley at Knightscope's Headquarters and machines are beginning to ship to a variety of clients awaiting fulfillment of their contracts across the country.

09:31 EST General Motors says Global Product Development leader Doug Parks to retire - General Motors announced it is making several changes to its product development team and creating a new role to oversee its global regions. "These moves will streamline the organization, allow for faster implementation of new vehicle and technology programs, and accelerate the company's go-to-market strategies. This realignment is driven by the retirement of Doug Parks, GM executive vice president of Global Product Development, Purchasing and Supply Chain, after a nearly 40-year career at the company," GM stated. Ken Morris, currently vice president, Global Vehicle and Propulsion teams, will be promoted to senior vice president, Product Programs, Product Safety and Motorsports. Josh Tavel, currently global vice president of Customer Care and Aftersales, will be promoted to senior vice president of Energy Storage and Propulsion, R&D, and Manufacturing Engineering. GM also announced leadership changes to increase collaboration across its global markets. "We've spent years preparing GM to transition to an all-electric future, and Doug's leadership has been pivotal. We are grateful for his many contributions to GM's success. The changes we are announcing today will continue to drive technical excellence and deliver groundbreaking vehicles to our customers around the world," said GM Chair and CEO Mary Barra. Reference Link

09:25 EST Dun & Bradstreet's Bradstreet's Data Cloud and IBM's watsonx team on AI for biz - Dun & Bradstreet (DNB) and IBM (IBM), have announced a strategic collaboration that will bring together Dun & Bradstreet's Data Cloud and IBM's watsonx to help organizations responsibly expand their use of generative AI. Dun & Bradstreet also intends to leverage watsonx for its workflows and solutions, supported by IBM Consulting. Through this collaboration, Dun & Bradstreet and IBM aim to develop offerings for clients to use in their native workflows to drive generative AI adoption that can help achieve growth and efficiency across a variety of business functions. The offerings will leverage watsonx, IBM's next-generation AI and data platform, and draw upon Dun & Bradstreet's Data Cloud, containing more than half a billion private and public companies, market-leading Identity Resolution, including the D-U-N-S Number and the company's generative AI capabilities.

09:19 EST AGS partners with Three Rivers Resort for table games floor - Three Rivers Casino Resort in Florence, Oregon upgraded its casino floor last month to exclusively utilize AGS table products. Included in the installation are 12 of AGS' progressive systems Bonus Spin Xtreme, which links all table games on the floor to form a single progressive jackpot. This install marks the first Bonus Spin Xtreme progressive in Oregon and the nationwide launch of Bonus Spin Xtreme on a craps table.

09:08 EST Marcus & Millichap, EquityMultiple partner for real estate investment products - EquityMultiple announced a partnership with Marcus & Millichap. Since inception in 2015, EquityMultiple has developed a more targeted, institutional approach to the real estate crowdfunding concept. While other brands in the space have taken on venture capital funding, EquityMultiple has grown its business and portfolio through strategic partnerships and a disciplined focus on asset management. Through its nationwide network of nearly 50,000 self-directed investors, EquityMultiple has provided financing for hundreds of real estate transactions. EquityMultiple looks forward to bringing these benefits to Marcus & Millichap's network of sponsors, operators, and brokers. The partnership also brings clear benefits to individual investors seeking streamlined access to a broader set of opportunities.

09:05 EST Alset executes binding term sheet to acquire 41.5% interest in New Energy - Alset announced the signing of a binding term sheet to acquire 100% of New Energy Asia Pacific. NEAPI owns approximately 41.5% of New Energy Asia Pacific Limited, a Hong Kong company. New Energy focuses on distributing all-electric versions of special-purpose and transportation vehicles, charging stations and batteries. NEAPI will be acquired from Mr. Heng Fai Chan, the Company's Chairman, CEO and largest stockholder. The consideration for the acquisition will consist of a convertible note in the amount of $103.75 million U.S. Dollars to be issued by the Company to the seller. Such convertible note will have a five year term and an interest rate of three per year. The note may be converted into shares of the Company's common stock by either party, at any time during the term of the note. The conversion price for such note has been set at $12.00 per share which is equivalent to approximately 16 times the last market trading price of AEI of $0.75 as of December 12, 2023. The closing of this acquisition will be subject to certain standard closing conditions. Currently, New Energy has a strong pipeline of demand, with signed collective sales secured via Memorandums of Understanding totalling up to $42 million in value and continues to garner strong interest from local government departments and market demand. New Energy will seek to significantly increase revenues in the coming months relating to both electric chargers and electric vehicles

09:02 EST Truist Financial names Scott Stengel as chief legal officer - Truist Financial announced that Scott Stengel will join the company on December 26, 2023, as senior executive vice president and chief legal officer, succeeding Ellen Fitzsimmons who previously announced her plans to retire at the end of this year following a distinguished career. Stengel will report to Truist Chairman and CEO Bill Rogers, serve as corporate secretary to the Truist Board of Directors and become a member of the bank's operating council. He'll be based in Charlotte, at the Truist corporate headquarters, where he'll oversee all legal affairs and government relations.

09:02 EST Senmiao Technology reports ride-hailing platform metrics for November - Senmiao Technology announced the operating metrics for its proprietary online ride-hailing platform for the month of November 2023. In November 2023, Senmiao and its affiliates recorded more than 0.48M total completed orders, compared to approximately 0.57M total orders completed in October 2023. The decrease was primarily a result of reduced demand for online ride-hailing services in a softer economic environment, as well as the ongoing impact of the compliance checks by Gaode, Senmiao's online ride-hailing platform partner under the original model, in Chengdu, one of the main cities where Senmiao operates. Numbers reported include the number of completed orders from several ride-hailing platform partners in Chengdu, utilizing Senmiao's network of cars and drivers for a set monthly fee. Since the launch of Senmiao's online ride-hailing platform in October 2020, approximately 25.8M rides have been completed using its own platform. More than 9.1M rides have been completed on several platforms in partnership with Senmiao under the new model3. The number of drivers completing rides via all the platforms in November 2023 was 5,240, compared to 5,903 in October 2023.

08:56 EST Paratek announces inclusion of oral NUZYRA in China's NRDL - Paratek Pharmaceuticals announced that China's National Healthcare Security Administration has added the oral formulation of NUZYRA to the country's National Reimbursement Drug List for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Earlier this year, NHSA added the intravenous formulation of NUZYRA to the NRDL for the treatment of CABP and ABSSSI. NUZYRA was granted approval by the U.S. Food and Drug Administration in October 2018 and Paratek launched the product in the United States in February 2019. Paratek's partner in China, Zai Lab, received approval of both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration of China for the treatment of CABP and ABSSSI in December 2021.

08:49 EST WISeKey's SEALSQ completes development of RISC-V post quantum test-chip - WISeKey International's (WKEY) SEALSQ Corp (LAES) completed the development of a RISC-V post quantum test-chip, an important milestone in the development of a new generation of RISC-V Quantum Resistant Secure Platform. This new generation chip based on the RISC-V open-source core technology, is meant to align not only with today's highest security standards like Common Criteria EAL5+ and NIST-FIPS, but also to be capable to run quantum resistant cryptographic algorithms to support next generation hybrid schemes. These include robust techniques like lattice-based and code-based cryptography, which are designed to withstand quantum computing threats.

08:46 EST Delaware DHSS selects Conduent to implement Maven management system - Conduent Incorporated announced that the Delaware Department of Health and Social Services Division of Public Health has selected the company's Maven Disease Surveillance & Outbreak Management System to replace its legacy public health surveillance systems. The agency will use Conduent's cloud-based technology platform to monitor, report and understand public health threats and infectious disease outbreaks as well as securely track patients and exposed communities.

08:41 EST Nextech3D.AI granted patent for generating 3D models from CAD data - Nextech3D.AI announced the grant of a patent by USPTO for 3D model generation from Computer Aided Design data. Receiving this first patent, as part of the Company's previously announced portfolio of patents filed in 2022, reinforces and validates Nextech3D.ai's commitment to increasing shareholder value by investing in 3D technology and innovating with AI-powered solutions. This patent enables Nextech3D.ai to increasingly capture a larger share of the rapidly growing 3D model creation business. There is growing demand for 3D product models for real-life, with increasing adoption of virtual reality with the META Quest and augmented reality with Apple's eagerly anticipated Vision Pro, which uses 3D models to display objects to users. Similarly, websites and mobile phones use 3D models to display products on e-commerce websites, which enables users to get a better sense of what the product looks like from all angles and perspectives.

08:40 EST Twin Vee PowerCats, AquaSport announce launch of three boat models - Ywin Vee PowerCats announced the launch of three new boat models as it closes out the fourth quarter of 2023. The second-generation Twin Vee 400 GFX, the Aquasport 24 Center Console, and the Twin Vee 280 GFX Dual Console are the latest additions to the Company's diverse lineup of boats.

08:37 EST Loop Industries says Loop branded PET resin compliant for packaging applications - Loop Industries announced that its Loop branded PET resin has been tested and is compliant for use in packaging applications in the pharmaceutical industry. The rigorous requirements and standards outlined by the United States Pharmacopeia and the European Pharmacopeia ensure that materials used in pharmaceutical packaging maintain the highest levels of integrity and do not compromise the safety and efficacy of the enclosed products. Test results executed by a worldwide leader in laboratory testing services confirm that Loop's PET resin has successfully met these requirements, opening new possibilities for sustainable packaging solutions in the pharmaceutical industry. In addition to pharmaceutical packaging applications, Loop branded PET resin is also suitable for use in food-grade packaging, cosmetic packaging and polyester fiber textile applications.

08:35 EST Jin Medical announces portable bath selected for Lao Le Hui bathing project - Jin Medical announced the Company's portable nano-thermal therapy bath has been selected as the equipment for "Lao Le Hui" Assisted Bathing Project. This significant initiative is a collaborative effort between a recognized foundation for the elderly in Shanghai, prominent state-owned enterprises, and industry partners, with the noble purpose of providing compassionate care and assistance to disabled or semi-disabled elderly individuals residing in Shanghai. Over the next two years, the Project aims to serve the goal of 100,000 individuals and train 2,000 dedicated bathing attendants. The Project aims to establish service centers within communities, which ensures precise and targeted bathing services for the elderly living in nearby residences. Wang Erqi, Chairman and CEO of the Company, commented, "As a proud partner of the Project, we are fully committed to supporting its widespread adoption and growth. By providing state-of-the-art bathing equipment, we strive to enhance service quality and work closely with our esteemed partners to extend the benefits of this philanthropic endeavor to a larger population of elderly individuals."

08:34 EST LivaNova 'believes it has contained the cybersecurity threat' disclosed on 11/20 - In a regulatory filing, LivaNova stated, "LivaNova is providing an update on operations with respect to the cybersecurity incident initially disclosed on November 20, 2023. At this time, all of the company's manufacturing sites worldwide are substantially operating at normal levels. As previously disclosed, promptly after detecting the cybersecurity issue, the company began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The company took certain actions to remediate the issue, such as taking certain systems offline. Due to these and other measures, the company believes it has contained the cybersecurity threat though its investigation and mitigation efforts are ongoing. The company continues to assess the full impact of the cybersecurity event on its business, results of operations, cash flows and financial condition."

08:33 EST SeaStar Medical announces formation of Scientific Advisory Board - SeaStar Medical announces the formation of the SeaStar Medical Scientific Advisory Board. "Science and innovation are the foundational pillars of SeaStar Medical and key to our competitive advantage," said Eric Schlorff, CEO of SeaStar Medical. "We are grateful to be collaborating with this incredible group of top clinical experts and scientists as we continue to develop and commercialize our selective cytopheretic device. We plan to further broaden our SAB with relevant expertise as we expand beyond our initial AKI clinical programs into other therapeutic categories and indications."

08:32 EST Avidity Biosciences announces data from Phase 1/2 EXPLORE44 clinical trial - Avidity Biosciences announced positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44 clinical trial for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping. AOC 1044 delivered unprecedented concentrations of phosphorodiamidate morpholino oligomers in skeletal muscle with up to 50-times greater concentrations of PMO in skeletal muscle following a single dose compared to peptide conjugated PMOs in healthy volunteers. AOC 1044 was well tolerated, demonstrated statistically significant exon 44 skipping compared to placebo of up to 1.5% in healthy volunteers after a single dose of 10 mg/kg AOC 1044 and increased exon skipping in all participants. Avidity plans to provide a first look at AOC 1044 data in people living with DMD44 in 2H 2024. AOC 1044 is designed to deliver PMO to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene to enable dystrophin production. AOC 1044 has been granted Orphan Designation by the FDA and the European Medicines Agency, and Fast Track Designation by the FDA. AOC 1044 is the first of multiple AOCs the company is developing for DMD. AOC 1044 delivered unprecedented, dose-dependent increases in PMO concentrations in skeletal muscle following a single dose of 5 mg/kg or 10 mg/kg, providing up to 50-times greater concentrations of PMO in skeletal muscle when compared to a single dose of peptide conjugated PMOs in healthy volunteers. AOC 1044 produced statistically significant exon 44 skipping compared to placebo of up to 1.5% in healthy volunteers after a single dose of 10 mg/kg AOC 1044 at Day 29. AOC 1044 increased exon skipping in all participants.

08:31 EST CISO Global completes SOC 2 audit - CISO Global announced the completion of its SOC 2 Type II audit following a 12-month review period. Conducted by leading compliance assessor A-LIGN, a technology-enabled security and compliance partner, the audit validates its security controls and data privacy practices of the audited company align with the highest standards.

08:30 EST Precision BioSciences: iECURE approved for trial evaluating ECUR-506 - Precision BioSciences announced that its partner iECURE has received approval from the Australian Therapeutic Goods Administration for the initiation of a first-in-human Phase 1/2 trial evaluating ECUR-506, incorporating an ARCUS nuclease for the treatment of Ornithine Transcarbamylase OTC deficiency in pediatric or neonatal patients. "The acceptance of iECURE's Clinical Trial Application marks an important milestone for patients with OTC deficiency and for both the iECURE and Precision BioSciences teams. This is the first ARCUS in vivo gene editing program to progress into the clinic," said Michael Amoroso, Chief Executive Officer of Precision Biosciences. "We look forward to supporting iECURE's continued progress with this program while working expeditiously to advance our wholly-owned hepatitis B virus program towards an anticipated clinical trial application or CTA and/or investigational new drug or IND, filing in 2024."

08:16 EST Jeffs' Brands signs exclusive distribution agreement with Bolly Jon - Jeffs' Brands is continuing its latest market expansion through an exclusive distribution agreement with Bolly Jon. This partnership introduces the distribution of a line of hair products based on stem cell technology via the Amazon Marketplace by Jeffs' Brands. As previously announced on December 11, 2023, pursuant to the distribution agreement, Jeffs' Brants will have exclusive rights to sell and distribute on the Amazon Marketplace the hair products offered by Bolly Jon, for a period of approximately five years. Bolly Jon, known for its innovative approach to hair care, utilizes the power of stem cell technology to offer a unique range of products. The partnership with Jeffs' Brands will bring these cutting-edge products, including shampoos, hair masks, and serums, to a global audience via Amazon.

08:14 EST Coya Therapeutics' CEO gives update, sufficient cash for COYA 302 Phase 2 trial - As the year comes to a close, ... I am pleased to say that our team rose to the occasion. Throughout the year, we notched several "wins," culminating in a transformative licensing transaction, announced December 6th , with Dr. Reddy's Laboratories (RDY). This partnership for COYA 302 in Amyotrophic Lateral Sclerosisor ALS provides up to $733 MM in non-dilutive upfront payments and potential sales and regulatory milestones ...$677.25 MM in sales based milestones and net sales; $40 MM of development and regulatory milestones; $7.5 MM upfront payment, and $8.4 MM in aggregate milestone payments upon IND filing and first patient first dosed. Coya also successfully closed a private placement financing of $26.5 MM in gross proceeds, at a time when capital raising for biotech has been limited. We anticipate that the cumulative proceeds from these two transactions will finance us into 2026...Cash Runway into 2026. One of our key objectives for 2023 was to raise additional capital through business development or partnering transactions. This goal was successfully achieved on December 6th when we announced a significant partnership with DRL for the development and commercialization of COYA 302, our proprietary low dose IL-2 and CTLA-4 Ig . This partnership is important both financially and strategically. Financially, the cash proceeds from this partnership, combined with the proceeds from our private placement, is anticipated to provide a cash runway which extends into 2026. Consequently, we believe it will also provide sufficient cash resources to complete the Phase 2 trial of COYA 302 while retaining long-term financial growth from this asset in ALS. Proceeds to us from the partnership with DRL include a $7.5 MM upfront payment, $8.4 MM in aggregate milestone payments upon IND filing and first patient first dose of COYA 302 in a Phase 2 trial, $40 MM of development and regulatory milestones, $677.25 MM of sales-based milestones and net sales royalties from the low to middle teens.

08:09 EST Verb Technology's MARKET.live launches TV campaign to promote Drop Ship Program - Verb Technology announces a national television campaign, launching December 18, 2023, to promote its new Drop Ship Program. VERB engaged SmartMedia Technologies to develop and execute the campaign. The MARKET.live TV commercials will air all over the country on many popular networks and television programs. Viewers can simply scan an on-screen QR code during the TV spots and be taken directly to a new site dedicated to the new MARKET.live Drop Ship Program. The new MARKET.live Drop Ship Program is designed for the people who have dreamed of starting their own ecommerce business, but lacked the knowledge or experience necessary to get started. Subscribers will also have access to coaching from world-class experts to help them navigate their new business venture. "We're thrilled to be the catalyst to help entrepreneurs of all ages realize their dreams of starting their own ecommerce business," stated VERB CEO, Rory Cutaia. "Our drop ship program has been in development for quite some time as we tested and fined-tuned the offering. Unlike many drop ship programs that only offer entrepreneurs cheap, poor-quality products, subscribers to MARKET.live's Drop Ship Program will be able to choose from a vast quantity of products in numerous categories, from many of the high-quality brands, retailers and vendors on MARKET.live."

08:07 EST BioAtla hosting R&D Day to highlight BA3071 CAB-CTLA-4 Phase 1 data - BioAtla is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent. Key R&D Day Topics and Highlights: Preclinical data review of targeted, pH-dependent binding of BA3071 in the tumor microenvironment demonstrated complete tumor regression following BA3071 treatment. A Phase 1 dose-escalation study evaluated BA3071 monotherapy followed by combination with nivolumab, conducted in 18 patients who had prior PD-1 failure and a median of at least three prior lines of treatment: Across the 6 cohorts, best overall response observed with two confirmed responses; nine stable disease; More specifically, in the 350 mg cohort in combination with 240 mg nivolumab, meaningful clinical benefit was observed in three patients, including 1 CR, 1 PR, and 1 SD; No grade 4 related treatment-emergent adverse events were observed among 18 treated patients. A Phase 2 clinical study of BA3071 monotherapy and in combination with PD-1 inhibitor is currently underway

08:06 EST TFF Pharmaceuticals appoints Thomas King to board of directors - TFF Pharmaceuticals announced the appointment of Thomas B. King to its Board of Directors. From 2003 to 2016, Mr. King served as the President, CEO and Director of Alexza Pharmaceuticals.

08:05 EST Auddia appoints Mahoney as Chief Financial Officer - Auddia announced the appointment of John Mahoney to the role of Chief Financial Officer. Mahoney succeeds Tim Ackermann, who resigned June 30, 2023. Mahoney brings over twenty years of finance and operational experience in the services industry spanning both publicly traded and privately held companies. His Auddia appointment follows roles with Quality Biomedical where he served as CFO.

08:04 EST Nemaura Medical receives positive Nasdaq listing decision - Nemaura Medical announces that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel's decision.

08:03 EST Rezolute completes enrollment of RZ401 Phase 2 study in DME - Rezolute announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema. RZ402 is a selective and potent plasma kallikrein inhibitor being developed as a potential oral therapy for the chronic treatment of DME. The study is a multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a once daily oral monotherapy over a 12-week treatment period and four-week follow-up in participants with DME who are naive to, or have received limited anti-VEGF injections. Eligible participants were randomized equally to either a placebo control arm or one of three RZ402 active treatment arms at doses of 50, 200, and 400 mg. This proof-of-concept study was designed to enroll up to 100 participants to evaluate activity and safety by individual dose level and in pooled fashion. In the fourth quarter 2023, based on considerable momentum, the Company elected to keep enrollment open into December to include as many eligible patients as possible. Screening is now complete, and final study enrollment is expected to be approximately 95 participants. Additionally, although each participant has an assigned study eye, it is expected that a meaningful number of non-study eyes will be eligible for evaluation. Since DME results from a systemic vascular complication associated with diabetes, it commonly affects both eyes. RZ402, as an orally available systemic therapy, has the potential to treat both eyes simultaneously. As a result of the extension of the enrollment period, the Company now plans to report topline results in the middle of the second quarter 2024, rather than the end of the first quarter 2024.

08:02 EST Clear Secure and Healthix launch Individual Access Services - Healthix, a public Health Information Exchanges, or HIE which serves the greater southern New York region, and CLEAR announced they have launched Individual Access Services to empower consumers with free, easy and secure access to their healthcare data from more than 8,000 health facilities across New York State in a single portal. Healthix has also engaged its New York State HIE colleague, Hixny, to provide the patient portal technology which embeds CLEAR's identity verification technology to seamlessly verify a consumer's identity and provide them with secure and easy access to their health information. The partnership enables interoperability between health systems and health organizations across New York State, allowing patients to access their health records by simply verifying their identity with a selfie, and finding their aggregated records in a single portal. The partnership also relieves New York State healthcare providers from the process of manually generating temporary passcodes for each patient to retrieve their health records.

08:01 EST Leidos wins $700M NSA technology contract - Leidos was recently awarded a new prime contract to provide prototype and technology development support to the National Security Agency. The single-award, indefinite-delivery-indefinite-quantity contract has a value of $700M.

07:48 EST Nubia Brand International announces requests to reedem public shares - Nubia Brand International announced that, as of 5:00 pm Eastern Time on December 12, 2023, Nubia has received requests to redeem a total of 3,896,031 Nubia public shares, representing 99.4% of the total public shares of Nubia outstanding prior to the Redemption Deadline. As of December 12, 2023, the pro rata portion of the Trust Account each public share would be entitled to receive upon redemption is approximately $10.94 per share. If all of the redemption requests received by Nubia as of the Redemption Deadline are satisfied by Nubia, 23,586 public shares of Nubia would be outstanding. Nubia will hold a special meeting of stockholders via live webcast at https://www.cstproxy.com/nubiabrandinternational/sm2023 on December 14, 2023 at 9:00 a.m. Eastern Time for its stockholders of record as of November 6, 2023 to approve the proposed business combination with Honeycomb Battery Company and related matters. Nubia stockholders are urged to read the proxy materials, including, among other things, the reasons for the unanimous recommendation by Nubia's Board that all stockholders vote "FOR" all proposals included in the definitive proxy statement/prospectus in advance of the Special Meeting by telephone, via the Internet or by signing, dating and returning the proxy card upon receipt by following the instructions on the proxy card.

07:40 EST Protagonist earns $10M payment for milestone in Phase 2b ANTHEM-UC study - Protagonist Therapeutics (PGTX) has earned a $10M milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis. With this additional payment, the Company has now earned $60M in payments in the fourth quarter of 2023 for milestones achieved in the JNJ-2113 Phase 2b and Phase 3 clinical programs led by the Company's collaboration partner, Janssen Biotech, Inc., a Johnson & Johnson company (JNJ). In addition to the $10M milestone payment related to the ANTHEM-UC trial, Protagonist earned a $50M milestone payment related to initiation of the ICONIC Phase 3 psoriasis program in October 2023. The Company remains eligible for up to an additional $795M in other development and sales milestone payments with respect to JNJ-2113 or other licensed IL-23 receptor antagonist oral peptides. The additional $795M in potential milestones include a $115M milestone for meeting the co-primary endpoints in any of the ICONIC Phase 3 psoriasis clinical trials, a $50M milestone upon NDA submission and a $35M milestone upon NDA approval. The Company is also eligible to earn upward tiering royalties of 6%-10%, with the 10% tier applicable for net sales of greater than $4B.

07:37 EST Guru Organic Energy launches Fruit Punch on Amazon.com - GURU Organic Energy Corp. (GUROF) announced that American consumers can now purchase its 2023 energy drink innovation, Fruit Punch, on Amazon.com (AMZN) and directly on the Company's website at www.guruenergy.com. GURU's Fruit Punch will also be available at select retailers across the United States starting in January 2024. The online launch of Fruit Punch in the US follows GURU's strong Black Friday and Cyber Monday sales performance on Amazon, which saw an outstanding growth of 295% in the US, as compared to the same period last year.

07:37 EST Beam Global appoints Syllantavos to board of directors - Beam Global announced that George Syllantavos, based in Europe, has joined the Beam Global board of directors. He joins Beam Global's board as an independent board member based in Europe and brings a strong track record in multiple public listings, M&A transactions, IPOs and the capital markets. George Syllantavos' previous board experience includes public companies Cepton Technologies, ITHAX Acquisition Corp., and and Star Maritime Acquisition Corp.

07:35 EST Vista Outdoor, Sport Dimension announce license renewal for Jimmy Styks brand - Vista Outdoorand water sports products manufacturer Sport Dimension announced the renewal of their Jimmy Styks brand license with a global, multi-year partnership. Jimmy Styks, a portfolio brand of Revelyst, the recently renamed Outdoor Products segment of Vista Outdoor, is a stand-up paddleboard SUP market leader, dedicated to cutting-edge design and quality manufacturing of SUP products and accessories. Vista Outdoor acquired Jimmy Styks in 2015 and began a brand license partnership with Sport Dimension Inc. in 2020. Jimmy Styks' SUP portfolio provides easy-to-use platforms for water sport enthusiasts engaging in activities ranging from personal fitness to fishing. The company offers nearly 30 SKUs in epoxy and inflatable boards, as well as accessories. The brand, which is part of Revelyst's Outdoor Performance platform, offers key water sports growth opportunities for Revelyst following Vista Outdoor's planned separation of its Outdoor Products segment into a standalone public company. "We are excited to announce the continuation of our brand license partnership with Sport Dimension Inc., which will keep the Jimmy Styks legacy intact for years to come," said Jordan Judd, President and General Manager, Outdoor Performance, Revelyst. "The brand's inflatable paddleboards, kayaks and accessories are unsurpassed in the market, having received accolades in numerous publications for innovative, user-friendly designs. Having a category leader like Jimmy Styks is a boon for Revelyst as we look to grow the brand's product offering and market reach."

07:33 EST Lifecore remains 'actively engaged' in evaluation of strategic alternatives - Lifecore Biomedical, Iprovided a business update. Lifecore is making significant progress towards completing its Annual Report on Form 10-K for the fiscal year ended May 28, 2023, which will include the previously disclosed restatements for prior fiscal periods. The Company expects to file the 2023 Form 10-K in the near term. The Company's work on its Quarterly Report on Form 10-Q for the fiscal quarter ended August 27, 2023, is expected to commence immediately following the completion of its 2023 Form 10-K and be filed upon completion. Lifecore continues to advance its development portfolio with new and existing customers and is currently working on the validation activities of its newly installed five-head high-speed isolator filler. For the fiscal second quarter ended November 26, 2023, the Company added one additional project for a total of 32 projects in development and its development pipeline continues to be active with multiple opportunities across pre-clinical through late-phase of development as well as commercial tech transfers. Lifecore remains actively engaged in its evaluation of potential strategic alternatives, which remains ongoing. As previously announced, the Company has not set a timetable for completion of this strategic review process, nor has it made any decisions related to its strategic alternatives at this time. There can be no assurance that this strategic review will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, or at all.

07:32 EST Distribution Solutions announces $25M share repurchase authorization - Distribution Solutions announced that its board of directors has approved a common share repurchase authorization of $25M. This authorization is in addition to approximately $4M still available under previous authorizations. During fiscal year 2023 to date, the company has repurchased approximately $3.6M of its common stock.

07:31 EST Ocugen doses first patient in Phase 1/2 clinical trial of OCU410 - Ocugen announced that the first patient has been dosed in the ArMaDa Phase 1/2 clinical trial of OCU410, a modifier gene therapy product candidate being developed for dry AMD. This Phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic atrophy secondary to dAMD and will be conducted in two phases. Phase 1 is a multicenter, open-label, dose-ranging study. Phase 2 is a randomized expansion phase in which subjects will be randomized in a 1:1:1 ratio to either one of two OCU410 dose groups or to an untreated control group.

07:27 EST Verastem initiates RAMP 301 trial - Verastem announced that it has initiated its international confirmatory Phase 3 RAMP 301 trial, evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer, or LGSOC. RAMP 301 is the confirmatory study required by the FDA for the combination of avutometinib and defactinib to potentially receive full approval for the treatment of recurrent LGSOC. The company intends to submit an accelerated approval new drug application, or NDA, for the combination of avutometinib and defactinib based on mature data from the Company's Phase 2 registration-directed RAMP 201 trial, together with the results of the investigator-initiated FRAME trial. The company recently reported results of Part A of the RAMP 201 trial, including confirmed objective response rates, or ORR, by blinded independent central review of 45% with a response rate and safety profile consistent with previous studies.

07:20 EST Flyht Aerospace signs multiyear contract renewal with Jordan Aviation - FLYHT Aerospace Solutions signed a multi-year contract renewal with Jordan Aviation PSC, to provide its fleet of Boeing 767, 737's and Airbus A320's with FLYHT's software solutions. The renewed agreement will help continue to improve JAV's flight operations and maximize its efficiency. This renewal extends the relationship between FLYHT and JAV that began in 2009 and currently includes a suite of software services that includes Satcom, FLYHTLog, FleetWatch, FLYHTHealth and FLYHTQAR on five aircraft. This contract renewal is valued at approximately $583,000, provided that all services are delivered over the five-year term of the agreement.

07:15 EST Reunion Gold announces additional drill results from Oko West project - Reunion Gold announced additional drill results from its Oko West project, Guyana and provides an update on the Oko West development studies. Highlights from the resource expansion drilling program beneath the June 2023 Mineral Resource Estimate pit shell between approx. 500 m to 1,000 m include Holes: D-336 intersecting 33.0 m @ 7.26 g/t Au; D-346A-W1 intersecting 13.0 m @ 8.41 g/t Au and 12.3 m @ 10.36 g/t Au; and D-347-W2 intersecting 17.4 m @ 4.92 g/t Au and 13.4 m @ 5.09 g/t Au; Highlights from resource conversion drilling above approx. 500 m include Holes D-343 intersecting 110.6 m @ 2.77 g/t Au; D-340 intersecting 105.1 m @ 2.15 g/t Au; and D-342-W1 intersecting 88.7 m @ 2.45 g/t Au; Resource expansion drilling at depth below the MRE pit continues to indicate that the high-grade zone identified within the MRE in block 4 continues to a depth of at least 1000 meters. Rick Howes, President and CEO of Reunion Gold, stated: "We are pleased with the results of the deep drill program which continues to indicate that the high-grade zone that was identified within the MRE in Block 4, continues to a depth of at least 1000 meters and is open below that. We expect this resource expansion drill program to be completed early in 2024 and those results will be included in the resource. The resource will include both an updated pit constrained resource in the area above 500 m and an initial resource in the area down to a 1,000-meter depth. We remain on track to release a Preliminary Economic Assessment in Q2/24, which will include this resource update and investigate the potential for a combined open pit and underground mining operation. We also continue to explore other areas of the Oko West prospecting license for potential satellite deposits." The latest results from the deep drilling resource expansion program between approx. 500 meters to 1,000 meters depths are reported in Table 1 and shown in Figure 1. Highlights of this drilling include: Hole D-336 which intersected 33 m @ 7.26 g/t Au to a depth of approx. 805 m, within a broader interval of 78.2 m @ 3.45 g/t Au; Hole D-346A-W1 which intersected 13.0 m @ 8.41 g/t Au and 12.3 m @ 10.36 g/t Au to a depth of approx. 820 m, within a broader interval of 82.6 m @ 3.7 g/t Au; Hole D-342-W1 intersecting 4.6 m @ 9.58 g/t Au and 9. 5 m @ 5.61 g/t Au to a depth of approx. 660 m, within a broader interval of 88.7 m @ 2.45 g/t Au and Hole D347-W2, which intersected 17.4 m @ 4.92 g/t Au and 13.4 m @ 5.09 g/t Au to a depth of approx. 1029 m within a broader interval of 68.7 m @ 2.80 g/t Au. The high-grade results reported above are calculated using a 1.5 g/t Au cut-off while the broader intervals reported were calculated using a 0.3 g/t Au cut-off. Results from the resource conversion drill program continue to demonstrate the strong level of continuity and consistency of the Oko West deposit. Drilling for this program is expected to be completed shortly and the results will be included in the planned resource update in Q2/2024. Highlights from the resource conversion drilling include Hole D-343 intersecting 110.6 m @ 2.77 g/t Au; Hole D-340 intersecting 105.1 m @ 2.15 g/t Au; Hole D-335 intersecting 121.6 m @ 1.59 g/t Au; and Hole D-339 intersecting 46.0 m @ 3.10 g/t Au. These results are reported using a 0.3 g/t Au cut-off grade.

07:13 EST Green Thumb Industries to open RISE Dispensary in Port Orange, Florida - RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries, announced that RISE Dispensary Port Orange, the Company's 14th location in Florida and 90th nationwide, will open on December 15. "We are thrilled to expand our presence on the east coast of Florida with the opening of RISE Port Orange," said Green Thumb President Anthony Georgiadis. "This store marks our first RISE location in Volusia County and the seventh new store we have opened in the Sunshine State this year. We look forward to welcoming more patients to the RISE experience and making a positive impact in the local community."

07:11 EST Next Hydrogen Solutions secures follow-on purchase order from Casale - Next Hydrogen Solutions has received a purchase order from Casale for development work related to integration of Next Hydrogen's next generation products for use in Casale's green ammonia and methanol systems. This work advances the partnership between Next Hydrogen and Casale established under the previously announced Memorandum of Understanding. The purchase order will support testing various operational profiles of Next Hydrogen's unique electrolysers to allow their optimization and integration into Casale's green ammonia and methanol plants.

07:11 EST MYnd Analytics completes merger transaction - Mynd.ai announced the successful completion of the merger transaction by which Gravitas Education Holdings, acquired Elmtree from Best Assistant Education Online Limited, a subsidiary of NetDragon Websoft Holdings. In connection with the Merger Transaction, GEHI has changed its corporate name to "Mynd.ai, Inc." and its ticker symbol from "GEHI" to "MYND". The CUSIP of the Company's American Depositary Shares will be changed to 628988 107. The ISIN of the Company's ADSs will be changed to US6289881079. All of the aforementioned changes were effective prior to 7:00 A.M. on December 13. The ADSs of the Company are expected to start trading under the new name and ticker symbol on the NYSE American on December 13. Effective immediately upon the close of the Merger Transaction, the following individuals became the executive officers of Mynd: Vincent Riera as the CEO, Arthur Giterman as the CFO, Matthew Cole as the Executive Vice President - Global Sales, Lance Solomon as the Chief Product Officer, Allyson Krause as the Executive Vice President and the General Counsel, Paul Heffernan as the Executive Vice President - Operations, Ronan O'Loan as the Chief Human Resources Officer. Mynd Substantially Advances its Capital Structure and Liquidity with the Issuance of $65 Million Senior Secured Convertible Notes. On the Closing Date, concurrent with the consummation of the Merger Transaction, the Company closed a private offering of $65M principal amount of senior secured convertible notes. The Notes will mature on December 13, 2028, unless earlier converted, redeemed or repurchased. The Notes are guaranteed by Promethean World Limited, a wholly-owned subsidiary of eLMTree, and secured by all of the shares of Promethean World.

07:09 EST Avacta Group provides data from Phase 1a dose escalation study of AVA6000 - Avacta Group provides detailed pre-clinical, clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre CISION programme, AVA6000, a tumour activated form of doxorubicin. The key conclusions drawn from the data for AVA6000 to date are: The pre CISION platform targets the release of a chemotherapy to the tumour as intended. The data show that the pre CISION modification is cleaved specifically by Fibroblast Activation Protein, an enzyme present in high concentrations in many solid tumours compared with healthy tissue. In the case of AVA6000, this targets the release of doxorubicin to the tumour microenvironment, concentrating the active cytotoxic drug within the tumor microenvironment and limiting systemic exposure to the chemotherapy. AVA6000 has significantly improved the safety and tolerability of doxorubicin. A significant reduction in the frequency and severity of the known doxorubicin toxicities has been observed across the dosing range. A maximum tolerated dose has not been reached in the three-weekly dose escalation study despite dosing approximately 3.5x the normal level of doxorubicin in the highest and final dose cohort in this part of the Phase 1a study. AVA6000 has shown encouraging preliminary clinical signs of anti-tumour activity. Preliminary results in the Phase 1a trial demonstrate activity of AVA6000 in patients with tumours with high FAP activity, validating the mechanism of action of AVA6000. For example, a 59-year-old male patient with Undifferentiated Pleomorphic Sarcoma has shown a reduction in tumour volume of 65% with a duration of response greater than6 months and ongoing. A number of other patients with different cancer types have shown smaller ongoing reductions in tumour volume or stable disease. The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre CISIONTM targeting. Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.

07:07 EST GreenPower manufactures of first electric school buses in West Virginia facility - GreenPower Motor announced that the company has completed manufacturing of its first four all-electric, purpose-built school buses at its West Virginia facility. The Type A Nano BEAST school buses will roll out of the facility today and be delivered to Cabell County, Clay County, Kanawha County and Monongalia County school districts in West Virginia this week. GreenPower took possession of the 80,000-square-foot facility in August of 2022 and since that time has prepared for the production of both the Type A Nano BEAST and the Type D BEAST all-electric, purpose-built school buses. The Nano BEAST has been in production since June and production of the BEAST will begin Q1 of 2024.

07:06 EST Whitestone REIT board unanimously rejects proposal by Bruce Schanzer - Whitestone REIT announced that, after careful review and consideration, the Board of Trustees of Whitestone has unanimously rejected a proposal by Bruce Schanzer, Chairman of Erez, demanding a majority change in our Board of Trustees with the sole purpose of embarking on an immediate sale or liquidation of Whitestone, without regard for maximizing long-term value for shareholders. For the sake of transparency, to maintain open communication with its shareholders, and to minimize misinformation regarding this matter, the Board has decided to release its response publicly. The letter read in part, "We understand Erez owns shares of Whitestone and that you intend to nominate four Board members. The Board of Trustees continuously evaluates all avenues to maximize value for our shareholders and is always committed to advance their best interests. After carefully reading your letter dated November 6, 2023, and reviewing the discussion with management on December 6, 2023, we understand that you view "a sale of assets or of the company outright" as the only way to drive value at the Company. However, the proposal consists of replicating the strategy employed at Cedar, without giving much consideration to how our portfolio, capital structure and business strategy might differ from that of Cedar. Furthermore, you do not seem to account for how current market conditions stand in contrast to those under which the Cedar transaction occurred. Finally, you ignore the strong total shareholder returns we have generated recently. Since the beginning of 2022, Whitestone has delivered +26% total shareholder return, far outpacing the average total shareholder return of negative for other shopping center REITs. This underscores the progress the Company has made since early 2022 under its new management team by staying focused on executing its business strategy. Your primary argument to justify your demand for four Board seats and the immediate actions outlined in your letter is that small cap REITs, such as Whitestone and Cedar, are forever precluded from achieving attractive results, driving shareholder value or bridging the gap to NAV. We strongly disagree as our business strategy has already achieved significant value creation for our shareholders and represents a clearer route to successfully maximize shareholder value. Once again, we think that our shareholder returns under our new CEO and executive team since early 2022 speak for themselves. With respect to your threat to nominate four Board members for election at our 2024 annual meeting: given the size of our current Board, your proposed four candidates would constitute a change in the majority of the Board. This is particularly concerning since your only stated objective is to embark on an immediate sale or liquidation of the Company, and you seem otherwise unable to articulate other means to drive shareholder value and unable to explain how any of your proposed Board nominees would add value to our Board and our shareholders. As a Board focused on the best interests of its shareholders, we take our fiduciary duties seriously and we have been proactive in both Board refreshment and in expanding the diversity and skillset of our Board. We have established procedures to consider any Board nominations, but we obviously cannot do so for unidentified nominees. While decisions on Board composition ultimately rest with our shareholders, we reject a proposal for majority Board change with the sole purpose of immediately effecting a sale or liquidation of Whitestone without regard for maximizing long-term value for shareholders."

07:04 EST Sonoco implementing $50 per ton price increase for recycled paperboard - Sonoco announced it is implementing a $50 per ton price increase for all grades of uncoated recycled paperboard in the United States and Canada, effective with shipments beginning February 1, 2024. This price action is necessary to offset increased input costs.

07:03 EST Black Diamond Therapeutics announces results from Phase 1 trial of BDTX-1535 - Black Diamond Therapeutics announced topline results from the dose escalation portion of the Phase 1 clinical trial of BDTX-1535 in patients with recurrent glioblastoma who expressed epidermal growth factor receptor (EGFR) alterations at the time of their initial diagnosis. Clinical data as of November 2023 reflect 27 patients with recurrent GBM who received a range of doses spanning 15mg to 400mg once daily in the dose escalation cohort. Combined pharmacokinetic (nd safety data from these 27 patients with GBM and 27 patients with NSCLC were previously presented on October 14, 2023 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. No new safety signals were observed; adverse events were consistent with the EGFR tyrosine kinase inhibitor class of drugs, including primarily Grade 1 and 2 diarrhea and rash. Key results: Of the 22 patients evaluable for efficacy, 3 patients were on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months. Historical progression-free survival in this population is in the range of 2-4 months. The patient on therapy the longest remains on BDTX-1535 at 100mg QD for over 15 months with prolonged disease stabilization. This patient had previously progressed after 3 months of temozolomide treatment. Of the 19 patients with measurable disease by Response Assessment in Neuro-Oncology criteria, 1 patient achieved a confirmed partial response and 8 patients experienced stable disease. The patient with the PR stayed on treatment for longer than 4 months at 200 mg QD.

06:57 EST Xylem announces realignment of its reportable segments - Global water technology leader Xylem announced a planned realignment of its reportable segments to reflect the operating drivers of financial performance with greater transparency. The change is driven by the integration of the Evoqua acquisition completed earlier this year. Effective January 1, 2024, the new segment, Water Solutions and Services, or WSS, will unify Evoqua's legacy Integrated Solutions and Services, or ISS, segment with Xylem's legacy dewatering and assessment services businesses. In May , Xylem acquired Evoqua. In the process of integrating the two companies, opportunities emerged to accelerate synergy capture by bringing multiple services offerings together in a single segment. With this realignment, WSS will comprise ISS, Xylem's dewatering business, previously part of the Water Infrastructure segment, and the assessment services business, previously part of the Measurement and Control Solutions segment. WSS will deliver a greater breadth of services at scale and enable the Company's service force to address a variety of customer challenges with a unified customer experience. For FY24, the approximate proportion of total revenue per business segment is expected to be Water Solutions and Services, 30%, Measurement and Control Solutions, 20%, Water Infrastructure, 30%, and Applied Water, 20%.

06:53 EST Pfizer says FY24 guidance includes Seagen acquisition

06:49 EST Pfizer sees annual net cost savings of 'at least' $4B - Enterprise-Wide Cost Realignment Program now expected to deliver annual net cost savings of at least $4.0B, an incremental $500M versus mid-point of guidance range provided on August 1, 2023.

06:40 EST Scorpio Tankers provides update on Q4 Daily TCE Revenues and lease activity - Scorpio Tankers announces updates on Q4 Daily TCE Revenues and recent debt and lease activity. Average Daily TCE Revenue for vessel class for LR2 is $38,000, for MR $32.500, and for Handymax $30,000. Subsequent to debt and lease activity announced in Earnings Press Release on November 9th, the Company has recently committed to repaying the debt or lease financing obligations on 13 vessels consisting of: 32013 built MR product tankers that are currently financed as part of the IFRS 16 - Leases - 3 MR lease financing. The purchases are expected to occur in December 2023 for an aggregate amount of $29.1M; 4 2012 built MR product tankers that are currently financed as part of the BCFL Lease Financing. The purchases are expected to occur in December 2023 and January 2024 for an aggregate amount of $29.0M. 3 2014 built Handymax product tankers that are currently financed as part of the Prudential Credit Facility. These repayments are expected to occur in January 2024 for $33.7M. 3 2015 built MR product tankers that are currently financed as part of the 2021 TSFL Lease Financing. The purchases are expected to occur in March 2024 for an aggregate amount of $45.6M. Emanuele Lauro, Chairman and CEO, commented "The product tanker market remains strong, MR rates have led the way and we are seeing an improvement in LR2 rates as winter demand increases and Middle East refinery maintenance concludes. Our balance sheet continues to improve and the commitments to repay the debt or lease financing obligations on 13 vessels reflect our commitment to lowering leverage and borrowing costs." There is currently $288.2 million available under the revolving portion of the 2023 $1.0B Credit Facility.

06:36 EST Southwest now sees Q4 RASM nown 9%-10% year-over-year - In a regulatory filing, Southwest Airlines is providing updated guidance regarding selected financial trends. The company now sees Q4 RASM, year-over-year, down 9% to 10% vs. a prior view of down 9% to 11%. The company still sees Q4 ASMs, year-over-year, to be up about 21%. The company still sees Q4 CASM-X, year-over-year, to be down 16% to 19%. The filing stated: "Fourth quarter 2023 travel demand and yields continue to be healthy. Leisure demand remains strong with record revenue over the Thanksgiving holiday period. Close-in bookings, including managed business bookings, have performed at the better end of expectations in November and December-to-date. As a result, the company now expects fourth quarter unit revenues to improve to the better end of its previous guidance range, and continues to expect record fourth quarter operating revenues and record fourth quarter passengers. The company's expected ASM year-over-year growth range of 14 percent to 15 percent for full year 2023 remains unchanged. The company also continues to expect first quarter 2024 capacity to increase in the 10 percent to 12 percent range, and full year 2024 capacity to increase in the range of 6 percent to 8 percent, year-over-year. The annual goal for capacity beyond 2024 is now for low- to mid-single-digit year-over-year ASM growth with low-single-digit year-over-year trip growth. The planned capacity moderation, relative to the company's previous goal of mid-single-digit year-over-year ASM growth, is to support the company's long-term financial goal to deliver after-tax return on invested capital well above the weighted average cost of capital. The company's fourth quarter 2023 CASM-X guidance range remains unchanged and is inclusive of market wage rate accruals for all open labor contracts related to the fourth quarter 2023 time period." Reference Link

06:34 EST Centogene completes recruitment for EFRONT Study - Centogene announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia, or FTD. The EFRONT Study has been conducted with support from Alector, a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, including FTD. Having met this milestone, CENTOGENE will continue to work with its extensive network of 30,000 physicians and enroll patients in the EFRONT Study under its Cento-FTD Program to provide timely diagnosis and further unlock insights into this neurodegenerative disorder.

06:31 EST Carter's, Shipt expand partnership - Shipt is partnering with Carter's. The new partnership brings convenience and time-saving opportunities to Carter's customers during the holidays with the speed of delivery through Shipt. Consumers will now be able to access all of Carter's brands from the Shipt Marketplace, in addition to the Carter's app, for same-day delivery of apparel and other family needs to markets across the country, including Atlanta, Chicago, Dallas, Los Angeles, Miami, New York, and more, all powered by Shipt's reliable shopper network.

06:05 EST Energous and Identiv announce partnership - Energous (WATT) and Identiv, (INVE) have partnered to bring real-time asset tracking to supply chain and logistics applications. This collaboration aims to wirelessly power Identiv's ID-Pixels tags with Energous' PowerBridge technology, enabling accurate and reliable sensor measurements that can be used throughout the supply chain, including in cold chain logistics. The joint solution aims to deliver more reliable, consistent power than disposable batteries and charging cables to the thousands of IoT sensors deployed across the logistics industry, resulting in less maintenance, lower costs and shorter setup times, while also establishing greater precision, safety and ease of use.

06:05 EST Daqo New Energy subsidiary to invest RMB 7.5B to create industrial park - Daqo New Energy announced that its subsidiary Xinjiang Daqo has signed an investment agreement to create a silicon-based new materials industrial park. Located in Shihezi, China, the project covers two phases. The first phase of the project consists of 150,000MT of silicon metal production, 50,000MT of polysilicon, and 1.2M pieces of silicon seed rod, with an anticipated investment of approximately RMB 7.5B. The second phase of the project consists of 150,000MT of silicon metal production, 50,000MT of polysilicon, and 1M pieces of silicon seed rod, with an anticipated investment of approximately RMB 7.5B. The implementation of this project, as well as its construction and completion time, is contingent upon market conditions, Xinjiang Daqo's shareholder approval, as well as relevant government filings and approvals, including energy consumption approval. Based on the agreement, the project is expected to receive green electricity as well as renewable energy green power certificates.

06:03 EST IBM selected by NATO for cybersecurity posturing - IBM signed a contract with the NATO Communications and Information Agency, or NCI Agency, to help strengthen the Alliance's cybersecurity posture with improved security visibility and asset management across all NATO enterprise networks. Starting in January 2024, IBM Consulting Cybersecurity Services will be delivering a custom-made, performance-based Asset, Configuration, Patching and Vulnerability, or ACPV, Management Service to the Alliance. As part of the agreement, IBM Consulting will build a customized solution that provides a unified view of NATO's security posture. The company will deploy data analysis, asset discovery, integrations, and security experts to provide a consolidated 'single source of truth' on information about assets, configurations, vulnerabilities, and patches across NATO. This will improve the Alliance's visibility into cyber risks and empower it to manage potential issues with more ease and speed across its network. Cybersecurity functions across the NATO Enterprise will be able to use IBM Consulting's ACPV service as the interface to access and dynamically query asset and configuration data, with a special focus on vulnerability management.

06:02 EST Shattuck Labs announces data from Phase 1A/B clinical trial of SL-172154 - Shattuck Labs announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Initial data from the dose-expansion cohorts build on the complete dose-escalation data featured in a poster presentation on December 11, 2023 at the 65th ASH Annual Meeting. "Both the frontline HR-MDS and TP53m AML expansion cohorts enrolled quickly after completion of the dose escalation study in the middle of this year, and we are pleased to share initial efficacy data, which begin to demonstrate the activity of SL-172154 beyond what is expected of AZA alone. In dose escalation, we saw a monotherapy response to SL-172154 in a heavily pre-treated relapsed/refractory TP53m AML patient that allowed the patient to receive a stem cell transplant. That patient remains disease free." said Lini Pandite, MBChB, Chief Medical Officer of Shattuck. "In frontline, the rate of complete responses in both the HR-MDS and TP53m AML cohorts is already encouraging, and when coupled with the observation of peripheral blood count recovery in most patients that have not yet achieved a complete response, and the fact that many of these patients are very early in their course of treatment and have not yet reached the median time at which a complete response is expected for azacitidine, suggests that the complete response rate may continue to improve in the coming months. As a result, we have amended both studies to increase the sample size and look forward to providing another update by mid-year 2024."

05:25 EST Zai Lab announces updates on China NRDL - Zai Lab announced that the 2023 National Reimbursement Drug List, or NRDL, released by China's National Healthcare Security Administration, or NHSA, has been updated to include the following medicines and indications: Vyvgart is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis, or gMG, who are anti-acetylcholine receptor, or AChR, antibody positive; Nuzyra is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia, or CABP, and acute bacterial skin and skin structure infections, or ABSSSI and Zejula is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.

05:11 EST Nextracker surpasses 10 GW of smart solar trackers in the Middle East - Nextracker announced it has surpassed a corporate milestone of 10 GW of smart solar trackers either operational or under fulfilment for projects located in the Middle East, Africa, and India. In parallel timing with the United Nations COP28 Climate Change conference held in Dubai over the last two weeks, this milestone was achieved this month after securing significant orders in the region.